Use of mucin like cancer associated antigen (MCA) in the management of breast cancer. by Laurence, V. et al.
Br. J. Cancer (1991), 63, 1000 1004 t. Macmillan Press Ltd., 1991
Use of mucin like cancer associated antigen (MCA) in the management of
breast cancer
V. Laurence', M.A. Forbes2 & E.H. Cooper2
'Regional Radiotherapy Centre, Cookridge Hospital, Leeds LS16 6QB; 2Diagnostic Development Unit, Department ofChemical
Pathology, University ofLeeds, Leeds, UK.
Summary A study of the epithelial mucin marker MCA was made in 233 patients with breast cancer. Only
6% of 72 patients with Stage I-III disease had a raised MCA (>15 U ml-') when assessed following surgical
treatment of the primary tumour. Raised levels of MCA occurred in one out of 20 (10%) patients with stable
local recurrence, and six out of ten (60%) patients with progressive local recurrence. In 115 patients with
metastases 89 (77%) had a raised MCA, tumour extent and disease activity both influenced the MCA level.
The change of MCA level during the treatment of 11 cases of local recurrence and 55 cases of metastatic
disease showed a 64 and 84% concordance respectively with the change in clinical status. Coincidental
measurement of MCA and bone scans showed a raised MCA in one out of 63 (1.5%) patients with negative or
equivocal scans, and 26 out of 35 (74%) with positive scans. MCA provides a useful marker for the
monitoring of the treatment of local recurrence and metastatic disease, and an independent indicator of the
effects of changes in treatment.
Polymorphic epithelial mucins (PEM) are surface glyco-
proteins secreted by normal epithelia in large amounts into
the external environment of the body. The loss of polarity
and the disruption of the cellular barriers in cancer results in
PEMs being shed into the internal environment and appear
in increased concentration in the circulation (Hilgers et al.,
1988).
Several assays based on the detection ofepitopes on PEMs
have been described and some of them have been shown to
be potentially useful as tumour markers in breast cancer.
Human milk fat globule proteins and human breast cancer
cells have been used to raise monoclonal antisera that can
react with cancer associated PEMs both in tissues and in the
plasma.
Several commerical assays have been developed to measure
PEMs in breast cancer; the first was CA15.3 (Hayes et al.,
1986) and this has been followed by mucin like cancer
associated antigen [MCA], (Stahli et al., 1989), CA549 (Bray
et al., 1987), CA M26 and CA M29 (van Kamp et al., 1989).
So far the tests appear to have comparable sensitivities for
the detection of systemic breast cancer and all are more
sensitive than carcinoembryonic antigen. With the exception
of CA15.3 there are few reports of how these markers per-
form in the routine clinical management of breast cancer.
The preliminary reports on MCA have indicated that its
clinical value was most likely to be in the monitoring of
recurrent and metastatic disease (Bieglmayer et al., 1988;
Cooper et al., 1989; Rasoul-Rockenschaub et al., 1989).
In this paper we report the results of a study investigating
the relationship between serum MCA levels and the clinical
status of over 200 patients attending a regional radiotherapy
centre for the management and follow-up of post-operative
breast cancer. We report on the use of serial measurements
of MCA in patients receiving treatment for local and dissem-
inated recurrent disease, and on the use of the marker as an
adjunct to isotope bone scanning.
Patients and methods
Serum samples were collected from 233 patients with breast
cancer attending Cookridge Hospital, Leeds, between July
1988 and December 1989 (231 women and two men). There
were three patient groups: 72 patients attending for post-
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operative radiotherapy after primary local excision or
mastectomy; 128 patients with local or distant recurrence
attending for assessment and treatment with hormones, cyto-
toxic chemotherapy and/or radiotherapy; and finally 33
patients on routine follow-up who had symptoms requiring
investigation to exclude relapse.
Sera was collected from all patients at first assessment.
Sequential samples were obtained from 66 patients receiving
treatment who were under regular review. All serum samples
were stored at -20°C until use. Patient information was not
available at the time of serum marker assay, all samples
being coded.
Data were analysed at the end of the study period using
clinical information obtained from patients' notes, and blind,
from marker values. Patient groups were subdividied further
prior to analysis (see below).
Post-operative patients
Patients were staged according to the standard UICC (Inter-
national Union Against Cancer) breast cancer classification
system. All patients had limited staging with chest X-ray,
routine haematology and biochemistry screening. In addition,
some had isotope bone scans, but this was not routinely
performed. There were 28 patients with Stage 1, 32 with
Stage 2, and 12 with Stage 3 disease. One patient was subse-
quently found to have asymptomatic bony metastases on a
staging bone scan, one later developed local recurrence and
one developed widespread metastatic disease on follow-up.
These three patients have been used twice in the analysis
(with initial marker value in the post-operative disease group
and new marker value at the time of known change in
status).
Local recurrence
Twenty-nine patients had locally recurrent disease of the
breast, chest wall or regional nodes. Four of these patients
developed distant metastases later in the study and have been
included in both groupings in the analysis (with marker
values at entry and then at relapse). Thirty patients with
local recurrence were thus available for analysis at the com-
pletion of the study. We subdivided the group retrospectively
using information from their notes and without knowledge of
marker levels. Twenty patients were described as having
'stable disease' (S.D). Their lesions were static or responding
to treatment according to standard UICC criteria for a
minimum of 3 months after study entry and they remained
alive for a minimum of 6 months. Ten patients in this group
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had 'progressive disease' (P.D.). Their lesions progressed des-
pite treatment or they died within 6 months of entering the
study.
Metastatic disease
One hundred and fifteen patients in the study had distant
metastases. Ninety-nine had known metastatic disease at
study entry of whom 39 were continuing with established
treatment, 45 were commencing new treatment and 15 were
having new symptoms investigated. Ten patients on routine
follow-up found to have newly positive bone scans, together
with the six previously mentioned patients in the post-
operative and local recurrence groups, who subsequently
developed metastases, are also included in this group.
We sub-divided these patients according to known site,
tumour burden and disease activity at study entry. Any
patient with metastases in one site only was defined as having
'single site' disease whereas those with metastases in more
than one site were said to have 'multi-site' disease. Burden
described the volume of known disease. 'Low burden' (L.B.)
was defined as a single area within one site, such as one area
of increased activity on an isotope bone scan, or a single
pulmonary nodule on the chest X-ray. All other patients were
defined as having 'high burden' (H.B.) disease. 'Activity'
described the symptoms and response to treatment at study
entry. Those who were asymptomatic and/or responding to
treatment were said to have 'inactive disease' whereas those
with symptoms and/or progressive disease were said to have
'active disease'. Assessment of clinical response was accord-
ing to standard UICC criteria (Hayward et al., 1977) by the
patients' attending clinician without knowledge of marker
values. External review of response was not obtained.
Serial measurement ofMCA levels in patients receiving
treatment
Sequential samples were obtained from a group of 55
patients with metastatic disease and 11 with local recurrence,
all of whom were receiving treatment with hormones, chemo-
therapy and/or radiotherapy over 1 to 9 months (mean 3
months). Samples were taken monthly where practicable
from patients on chemotherapy and at each attendance for
follow-up from the rest (with a mean of three samples per
patient; range two to seven). The responses to treatment as
documented by the attending clinicians were compared to the
patients' changing MCA values over the same time period.
Disease status was defined as stable, progressive or respond-
ing according to standard UICC criteria. A change ofmarker
level of ± 20% over 6 months (or equivalent rate of change)
was considered to be significant.
Bone scans
Ninety-eight patients had isotope bone scans performed dur-
ing the study period for staging or as part of symptom
assessment. Serum samples were taken at the time of scan-
ning and independently evaluated. All scans were reported by
the patients own clinician to whom MCA values were un-
available.
Scans were classified as negative, positive or equivocal.
Positive scans were defined as 'low burden' (L.B.) if only one
site of increased activity was demonstrated and 'high burden'
(H.B.) for all others. The 13 equivocal scans were supple-
mented by plain X-rays and serum alkaline phosphatase
measurements. Eight were thought to represent degenerative
change, one to represent low burden metastases and four to
be of uncertain significance by the reporting clinicians.
MCA assay
The MCA-EIA (Roche Diagnostics, Welwyn Garden City,
Herts) was used according to the manufacturer's instructions.
The kit is a two-step solid phase enzyme immunoassay. The
assay employs the same monoclonal mouse antibody to
MCA (MAb b-12) in both positions of the sandwich (as
capture antibody and as detection antibody), as this antibody
recognises a repetitive binding site on the MCA molecule.
The inter-assay CV was 9.6% and the intra-assay 8.5%.
Statistical analysis
The Mann Whitney test was used to compare differences
between the groups.
Results
A previous study of the MCA levels in 63 tumour-free breast
cancer patients, 3-9 years after treatment ofprimary disease,
showed a median and range of 7.4 U ml-' (1-21.1) and was
similar to the levels found in healthy controls (Cooper et al.,
1989). Based on these results, the upper limit of normal
MCA in disease-free women was set at 15 U ml-l (mean + 2
s.d.). The marker displays a non-Gaussian distribution and
follows a log-normal pattern.
The results of initial marker values for the groups pre-
viously described above are shown in Table I. MCA levels of
> 15 U ml-' were present in 6% ofpatients with Stage I-III
disease, 27% with local recurrence and 77% of those with
metastatic disease. The ranges, median values and interquar-
tile ranges for these groups and their subgroupings are shown
in Figure 1. These were found to be significantly different
(P<0.05) between the three main groupings.
Table I MCA levels in various patient groups
Number Median Range of Number of % with Patient of MCA value MCA values patients with MCA
group patients Uml- Uml-' MCA>J5 Uml-' >15 Umlt
Post-operative
Stage I 28 7 0.7-16.5 1 4 Stage II 32 8.6 0.7-18 2 6 Stage III 12 11.6 1.1-21.5 1 8 All 72 8 0.7-21.5 4 6 Local recurrence
Stable disease 20 9.3 2-77 2 10 Progressive disease 10 21.5 10.5-77 6 60 All 30 11 2-77 8 27 Metastatic disease
Low burden
inactive 8 7.5 1.5-17.5 1 12.5 Low burden active 17 15.8 2-47 9 53 High burden
inactive 17 22 3.8-22 12 72 High burden active 73 75 6.3-2500 67 92 All 115 38 1.5-2500 89 771002 V. LAURENCE et al.
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Figure 1 Distribution of MCA levels in patients following sur-
gical treatment of primary breast cancer, with local recurrence
and with distant metastases. LBi = Low burden inactive; HBi =
High burden inactive; LBa = Low burden active; HBa = High
burden active; SD = Stable disease; PD = Progressive disease;
Horizontal line = 15 U ml-' [the upper limit of the normal
range].
In the post-operative group of patients with Stage I, II and
III disease, 4%, 6% and 8% respectively had raised marker
values. This represents a significant upwards trend for in-
creasing MCA value with increasing disease stage. Of the
four patients with raised markers two remained tumour free
at 9 and 11 months follow-up (MCA values of 16 and
18 U ml-'); one remained tumour free with falling markers at
3 months follow-up (from 16.5 to 13.5 U ml-'), and the
fourth patient with a value at the top of the range of
21.5 U ml-' was subsequently found to have asymptomatic
bony metastases. There were three further patients with
MCA values at the top of the normal range of 15 U ml-'. Of
these one remains well, one has developed local recurrence
(the only one from the post-operative group) with rising
titres of MCA and the third complained offfitting bone pains
2 months after operation and on isotope bone scanning was
shown to have bony metastases. She died of widespread
disease 3 months later. Her MCA value was 18 U ml' 1
week after the first sample and 103 U ml-' at the time of her
bone scan.
Of the 30 patients with local recurrence, 27% had raised
MCA values with a median of 11 U ml-' and a range of
2-77 U ml-'. Within this group those with progressive
disease had significantly higher values than those with stable
disease (P= 0.001). Seventy-seven per cent of the 115
patients with metastatic disease had raised markers with a
median value of 38 U ml- ' and range of 1.5-2,500 U ml1 '.
As shown in Figure 1, the greater the burden and activity the
higher the markers tend to be (P = 0.001 for high burden
against low burden).
Table II shows the numbers of patients with metastatic
disease as described by single or multiple site (i.e. more than
one site) and their MCA values. Most patients in the study
had either bony or multi-site metastases. Those with multi-
site disease had significantly higher marker values than those
with single sites (P = 0.001). There was no significant differ-
ence between marker values according to individual site.
Correlation ofchanging MCA levels with the clinical course of
disease.
Sequential samples were obtained from 66 patients receiving
treatment. Figure 2 shows the changing values over 2-8
months for the 55 patients with metastatic disease. Table III
shows the concordance values. Eighty-four percent of those
patients with metastatic disease and 64% of the 11 patients
with local recurrence had changing markers which corres-
ponded to their clinical status. Those with responding or
progressing metastatic disease had the highest concordance.
Those with clinically stable disease, but rising or falling
markers may be showing a lead time effect which will become
apparent on further long-term follow-up.
Figures 3 to 6 show the graphs of four individual patients
as examples of the MCA changes occurring over time.
Patient 1 had known metastatic disease in a number of sites
and was receiving single agent weekly chemotherapy at the
start of the study. In February 1989 her symptoms pro-
gressed and her treatment was changed. Despite this, her
condition deteriorated and she died in April 1989. As can be
seen from the graph, her MCA values over this time period
show a progressive rise. In comparision, Patient 2, a man
with nodal, pleural, and bony metastases, previously treated
with hormones, commenced weekly single agent chemo-
therapy in January 1989 with a good symptomatic and objec-
tive partial response which continued until July 1989. This
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Figure 2 Rates of change of MCA in patients with metastatic
disease on treatment according to response.
Table II MCA levels of patients with metastatic disease according to sites involved
Number Median Range of Number ofpatients % with
of MCA MCA values with MCA MCA >15
Site patients Uml-' Uml'] >15 Uml-' Umh'I
Central nervous 3 17 5.6-27 2 67
system
Liver 4 23 6.3-169 3 75
Lung/pleura 12 27 1.5-1360 9 75
Bone 52 27 2-399 37 71
Multi-site 44 70 6-2500 40 91MCA IN BREAST CANCER 1003
Table III Concordance ofchange of MCA level and clinical status
Number Appropriate
Clinical of MCA changes Concordance
status patients number %
Progression 26 24 92
Metastatic Stable 15 10 67
disease Responding 14 12 86
All 55 46 84
Progression 3 1 33
Local Stable 5 3 60
recurrence Responding 3 3 100
All 11 7 64
Total 66 53 80
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Figure 3 Progressive rise of MCA level in a patient with wide-
spread metastatic disease.
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Figure 4 Symptomatic improvement in a male patient after
changing from hormone to chemotherapy with corresponding fall
of MCA.
300 -
200 -
E
D
100-
60-
40-
Change chemo. Plone
Symptoms I
Asymptomatic
8 10 12 2 4 6 8
1988 1989
Figure 5 Fall of MCA following a change of chemotherapy in
metastatic disease.
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Figure 6 Change of MCA level in a patient with a local recur-
rence following post-operative radiotherapy for Stage II disease
that was not controlled by chemotherapy.
was mirrored by the falling MCA titres. Patient 3 had pro-
gressive disease which responded to a change in treatment
before progressing. Patient 4 was initially treated with
radiotherapy and adjuvant chemotherapy for Stage II
disease. She developed local recurrence within 6 months and
has progressive local disease despite further chemotherapy.
Bone scans
As described above, 98 patients had marker levels assayed at
the time ofassessment or staging with isotope bone scan. The
results are shown in Table IV. Only one patient (1.5%) with
a negative or equivocal scan had a raised MCA level (16.5 U
ml-') compared to 26 out of 35 patients (74%) with positive
scans (P = 0.001). The predictive value of a raised MCA for
a positive diagnosis was 96% and of a normal MCA for a
negative diagnosis 87%.
Discussion
A study of the MCA levels in women who have remained
tumour-free for several years after treatment of primary
breast cancer showed that the median and range is similar to
that of normal controls. Repeated annual measurements in
these patients show a narrow intra-patient variation
(<± 2.0 U ml-') even though the overall range was wide
(1-21 U ml-') and therefore interpretation of MCA changes
is easier if the patients' own tumour-free level is known
(Cooper et al., 1989).
For convenience we have used 15 U ml-' as the upper-
limit of normal, which is close to 14 U ml-' and 14.4 U ml-'
adopted by Bieglmayer et al. (1988), and Rasoul-Rochen-
schaub et al. (1989), but is higher than the 11 U ml1l advised
by the manufacturers. In earlier reports of MCA levels in
tumour free patients, Rasoul-Rochenschaub et al. (1989),
reported in 263 patients the mean ± s.e.m. to be 4.5 ± 0.3 U
ml-' and Cooper et al. (1989) found a median of 7.4 Uml-'
in 63 patients. Hence it is difficult to draw conclusions about
the significance of the post-operative levels when they are
based on a single reading. Three patients in the current series
showed evidence of recurrent or metastatic disease within 6
months of their post-operative assessment, their MCA levels
at the time of initial assessment being 15, 15 and 21.5 U mlhl
respectively. Bieglmayer et al. (1988), studied the change in
MCA levels in 49 high risk patients, 20% ofwhom developed
metastases during the observation period. A rising MCA
level was found to precede metastases in 91% with a lead
time of 1-15 months.
As the information on the use of breast cancer markers in
clinical practice increases it becomes clear that the epithelial
mucin markers CA15.3 and MCA have similar characteristics
in terms of their ability to reflect the progress of metastatic
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cancer (Bieglmayer et al., 1988; Rasoul-Rockenschaub et al.,
1989; Eskelinen et al., 1989; Colomer et al., 1989). When a
cut-off level is used based on controls or tumour free patients
it is evident that the percentage of raised markers in metas-
tatic disease studied vertically is influenced by the site, and
disease activity as shown in Tables I and II. In general
normal levels are more likely to occur when there is a low
tumour burden or inactive disease. A similar conclusion was
drawn by Colmer et al. (1989) in their study of CA15.3. In a
comparison of skeletal lesions with progressive and stable
disease the mean ± s.e.m. MCA levels were 39.3 ± 1.9 and
21 ± 1.0 U ml-' and for visceral lesions the levels were
49.3 ± 2.8 and 19.8 ± 1.0 U ml-' respectively (Rasoul-Rock-
enschaub et al., 1989). Comparable trends are shown in our
present study and that reported by Bieglmayer et al. (1989)
and Steger et al. (1989).
It appears that none of the mucin breast cancer markers
are sensitive to small tumour volumes in soft tissues, as
shown by primary tumours or localised recurrence (Cooper
et al., 1989; Bieglmayer et al., 1989; Bon et al., 1990). How-
ever, in local recurrence the more extensive and aggressive
lesions tended to have a raised MCA in our series.
It is clear from the relatively short term follow-up studies
shown in this report that it is the change of MCA level that
provides the most useful data for routine patient manage-
ment. There is a high concordance between the rate of
change of the marker levels and clinical and imaging evidence
of tumour progression, regression or stability. If measure-
ments are made during the first 2-3 weeks after a change of
treatment, the levels of the mucin markers may show the
expected rise during progression or fall during regression, but
an initial parodoxical surge can occur in the good responders
(Kiang et al., 1990). The measurement of MCA at the time
of performing a bone scan provides an adjunct to the inter-
pretation of the scan. In this series, raised MCA levels were
only seen in 1.5% of patients with negative and equivocal
scans while 74% of those with positive scans had raised
values.
Although MCA lacks the specificity and sensitivity to
make it an ideal cancer marker for breast cancer, it performs
better than CEA (Rasoul-Rockenschaub et al., 1989; Beigl-
mayer et al., 1989; Steger et al., 1989) as do the other
epithelial mucin breast cancer markers (Bon et al., 1990). Our
experience of using the test in a regional radiotherapy centre
suggests that MCA measurements can be helpful to the
clinician in the following circumstances. At presentation it is
valuable to obtain an initial value as an adjunct to staging
and to provide a reference value for subsequent monitoring;
at this time high values can draw attention to asymptomatic
metastatic disease and warrant study by bone and liver scans.
In metastatic disease the change of level of MCA is helpful in
assessing progress in patients without measurable lesions.
When there is doubt about the interpretation of a bone
scan such as a pattern of activity untypical of metastases,
then the marker level may help to distinguish degenerative
from metastatic disease. Similarly, a change in MCA level
may reinforce the clinical opinion that symptoms during the
follow-up period are likely to be due to recurrent disease
prompting further investigation. It must be kept in mind that
the mucin breast cancer markers can be raised in other
tumours such as those of the ovary, GI tract and lung
(Kenemans et al., 1988), as well as benign liver, and auto-
immune disease such as cirrhosis and SLE. An unexpected
rise in nadir must not be assumed to be due to recurrent
breast cancer but needs full evaluation. The markers, no
doubt, can be used as one parameter in the assessment of the
effects of new treatment regimes.
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